Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab
ConclusionsDenosumab preserves bone health as assessed by phalangeal QUS and DXA. Since inexpensive and radiation-free, phalangeal QUS may be considered in the follow-up of AIs-treated BC women receiving denosumab.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | DEXA Scan | Endocrinology | Orthopaedics | Ultrasound | Women | Xgeva